Loading...

Resonance Health

ASX:RHT
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RHT
ASX
A$48M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Resonance Health has significant price volatility in the past 3 months.
RHT Share Price and Events
7 Day Returns
0%
ASX:RHT
-1.8%
AU Medical Equipment
0.5%
AU Market
1 Year Returns
465.2%
ASX:RHT
-2.8%
AU Medical Equipment
4.9%
AU Market
RHT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Resonance Health (RHT) 0% 49.4% 54.8% 465.2% 712.5% 154.9%
AU Medical Equipment -1.8% -0.2% -1% -2.8% 40.5% 105.5%
AU Market 0.5% 1.9% 8% 4.9% 19.5% 6.3%
1 Year Return vs Industry and Market
  • RHT outperformed the Medical Equipment industry which returned -2.8% over the past year.
  • RHT outperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
RHT
Industry
5yr Volatility vs Market

RHT Value

 Is Resonance Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Resonance Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Resonance Health.

ASX:RHT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:RHT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.93 (1 + (1- 30%) (0%))
0.953
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.953 * 5.96%)
7.99%

Discounted Cash Flow Calculation for ASX:RHT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Resonance Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:RHT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 7.99%)
2019 1.38 Est @ 69.17% 1.27
2020 2.05 Est @ 49.12% 1.76
2021 2.77 Est @ 35.07% 2.20
2022 3.47 Est @ 25.25% 2.55
2023 4.11 Est @ 18.37% 2.80
2024 4.67 Est @ 13.55% 2.94
2025 5.14 Est @ 10.18% 3.00
2026 5.54 Est @ 7.82% 3.00
2027 5.89 Est @ 6.17% 2.95
2028 6.18 Est @ 5.01% 2.86
Present value of next 10 years cash flows A$25.34
ASX:RHT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$6.18 × (1 + 2.31%) ÷ (7.99% – 2.31%)
A$111.31
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$111.31 ÷ (1 + 7.99%)10
A$51.59
ASX:RHT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$25.34 + A$51.59
A$76.93
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$76.93 / 402.50
A$0.19
ASX:RHT Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.19
Current discount Discount to share price of A$0.13
= -1 x (A$0.13 - A$0.19) / A$0.19
32%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Resonance Health is available for.
Intrinsic value
32%
Share price is A$0.13 vs Future cash flow value of A$0.19113
Current Discount Checks
For Resonance Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Resonance Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Resonance Health's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Resonance Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Resonance Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:RHT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:RHT Share Price ** ASX (2019-04-24) in AUD A$0.13
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.61x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.19x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Resonance Health.

ASX:RHT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:RHT Share Price ÷ EPS (both in AUD)

= 0.13 ÷ 0.00

51.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Resonance Health is overvalued based on earnings compared to the AU Medical Equipment industry average.
  • Resonance Health is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Resonance Health's expected growth come at a high price?
Raw Data
ASX:RHT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 51.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Resonance Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Resonance Health's assets?
Raw Data
ASX:RHT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.01
ASX:RHT Share Price * ASX (2019-04-24) in AUD A$0.13
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.75x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:RHT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:RHT Share Price ÷ Book Value per Share (both in AUD)

= 0.13 ÷ 0.01

10.25x

* Primary Listing of Resonance Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Resonance Health is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Resonance Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Resonance Health has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RHT Future Performance

 How is Resonance Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resonance Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Resonance Health expected to grow at an attractive rate?
  • Unable to compare Resonance Health's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Resonance Health's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Resonance Health's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:RHT Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:RHT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:RHT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 1 1
2018-09-30 3 1 1
2018-06-30 3 0 0
2018-03-31 3 0 0
2017-12-31 3 0 0
2017-09-30 3 0 0
2017-06-30 3 0 0
2017-03-31 3 0 0
2016-12-31 3 0 0
2016-09-30 3 0 0
2016-06-30 3 0 0
2016-03-31 3 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Resonance Health is high growth as no earnings estimate data is available.
  • Unable to determine if Resonance Health is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:RHT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Resonance Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RHT Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Resonance Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Check out Resonance Health's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
  2. Resonance Health's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Resonance Health's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Resonance Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Resonance Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RHT Past Performance

  How has Resonance Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Resonance Health's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Resonance Health's year on year earnings growth rate has been positive over the past 5 years.
  • Resonance Health has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Resonance Health has become profitable in the last year making it difficult to compare the AU Medical Equipment industry average.
Earnings and Revenue History
Resonance Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Resonance Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:RHT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.42 1.04 2.33 0.10
2018-09-30 3.16 0.63 2.50 0.11
2018-06-30 2.90 0.22 2.66 0.12
2018-03-31 2.72 0.00 2.59 0.13
2017-12-31 2.55 -0.22 2.52 0.14
2017-09-30 2.53 -0.26 2.46 0.15
2017-06-30 2.51 -0.30 2.40 0.16
2017-03-31 2.51 -0.32 2.45 0.14
2016-12-31 2.51 -0.33 2.49 0.11
2016-09-30 2.53 -0.36 2.44 0.11
2016-06-30 2.55 -0.38 2.39 0.11
2016-03-31 2.60 -0.20 2.21 0.12
2015-12-31 2.65 -0.01 2.03 0.12
2015-09-30 2.63 0.23 1.93 0.10
2015-06-30 2.61 0.46 1.83 0.07
2015-03-31 2.55 0.49 1.73 0.07
2014-12-31 2.49 0.52 1.63 0.08
2014-09-30 2.39 0.23 1.66 0.07
2014-06-30 2.28 -0.07 1.68 0.07
2014-03-31 2.19 0.01 1.68 0.07
2013-12-31 2.09 0.10 1.69 0.07
2013-09-30 1.88 -0.05 1.67 0.06
2013-06-30 1.67 -0.20 1.66 0.06
2013-03-31 1.59 -0.34 1.66 0.06
2012-12-31 1.50 -0.48 1.66 0.07
2012-09-30 1.59 -0.38 1.68 0.08
2012-06-30 1.69 -0.27 1.70 0.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Resonance Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Resonance Health used its assets more efficiently than the AU Medical Equipment industry average last year based on Return on Assets.
  • Resonance Health has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Resonance Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Resonance Health has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RHT Health

 How is Resonance Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Resonance Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Resonance Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Resonance Health has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Resonance Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Resonance Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Resonance Health Company Filings, last reported 3 months ago.

ASX:RHT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.10 0.00 2.14
2018-09-30 5.10 0.00 2.14
2018-06-30 4.13 0.00 1.55
2018-03-31 4.13 0.00 1.55
2017-12-31 3.85 0.00 1.12
2017-09-30 3.85 0.00 1.12
2017-06-30 3.73 0.00 1.69
2017-03-31 3.73 0.00 1.69
2016-12-31 4.07 0.00 1.92
2016-09-30 4.07 0.00 1.92
2016-06-30 4.03 0.00 2.51
2016-03-31 4.03 0.00 2.51
2015-12-31 4.38 0.00 2.41
2015-09-30 4.38 0.00 2.41
2015-06-30 4.41 0.00 2.80
2015-03-31 4.41 0.00 2.80
2014-12-31 4.38 0.00 2.58
2014-09-30 4.38 0.00 2.58
2014-06-30 3.34 0.00 2.10
2014-03-31 3.34 0.00 2.10
2013-12-31 2.09 0.00 0.74
2013-09-30 2.09 0.00 0.74
2013-06-30 2.24 0.00 1.09
2013-03-31 2.24 0.00 1.09
2012-12-31 2.13 0.00 1.03
2012-09-30 2.13 0.00 1.03
2012-06-30 2.57 0.00 1.18
  • Resonance Health has no debt.
  • Resonance Health has not taken on any debt in the past 5 years.
  • Resonance Health has no debt, it does not need to be covered by operating cash flow.
  • Resonance Health has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Resonance Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Resonance Health has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RHT Dividends

 What is Resonance Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Resonance Health dividends.
If you bought A$2,000 of Resonance Health shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Resonance Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Resonance Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:RHT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Resonance Health has not reported any payouts.
  • Unable to verify if Resonance Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Resonance Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Resonance Health has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Resonance Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Resonance Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Resonance Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RHT Management

 What is the CEO of Resonance Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alison Laws
COMPENSATION A$535,475
TENURE AS CEO 1.2 years
CEO Bio

Ms. Alison Laws has been the Chief Executive Officer at Resonance Health Limited since February 2018. Ms. Laws joined Resonance Health in 2016. She served as Global Account Manager for Resonance Health. She has significant previous experience in building a software company. Prior to this, she lectured in Business Statistics and has worked in a range of Commercial analysis roles for small, medium and large businesses.

CEO Compensation
  • Insufficient data for Alison to compare compensation growth.
  • Alison's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Resonance Health management team in years:

1.8
Average Tenure
  • The average tenure for the Resonance Health management team is less than 2 years, this suggests a new team.
Management Team

Alison Laws

TITLE
Chief Executive Officer
COMPENSATION
A$535K
TENURE
1.2 yrs

Agha Pervez

TITLE
CFO & Company Secretary
COMPENSATION
A$185K
TENURE
1.4 yrs

Tim St. Pierre

TITLE
Chief Scientific Officer
COMPENSATION
A$207K
TENURE
16.3 yrs

Celine Royet

TITLE
Quality Assurance & Regulatory Affairs Manager
COMPENSATION
A$111K
TENURE
3.8 yrs

Jason Loveridge

TITLE
Corporate Advisor
COMPENSATION
A$40K
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure of the Resonance Health board of directors in years:

5.4
Average Tenure
  • The tenure for the Resonance Health board of directors is about average.
Board of Directors

Martin Peter Blake

TITLE
Non-Executive Chairman
COMPENSATION
A$60K
AGE
62
TENURE
8.3 yrs

Travis Baroni

TITLE
Non-Executive Director
COMPENSATION
A$40K
TENURE
2.4 yrs

Simon Panton

TITLE
Non-Executive Director
COMPENSATION
A$40K
TENURE
9.5 yrs

Mitchell Wells

TITLE
Non Executive Director
COMPENSATION
A$93K
AGE
43
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Resonance Health insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
05. Feb 19 Buy Simon Panton Individual 05. Feb 19 05. Feb 19 1,000,000 A$0.07 A$70,999
16. Nov 18 Buy Mitchell Wells Individual 14. Nov 18 16. Nov 18 400,000 A$0.03 A$10,371
06. Sep 18 Buy Simon Panton Individual 06. Sep 18 06. Sep 18 1,270,607 A$0.02 A$31,764
31. May 18 Buy Simon Panton Individual 29. May 18 29. May 18 68,525 A$0.02 A$1,576
29. May 18 Buy Simon Panton Individual 23. May 18 23. May 18 170,000 A$0.02 A$4,080
X
Management checks
We assess Resonance Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Resonance Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RHT News

Simply Wall St News

What Percentage Of Resonance Health Limited (ASX:RHT) Shares Do Insiders Own?

A look at the shareholders of Resonance Health Limited (ASX:RHT) can tell us which group is most powerful. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Resonance Health is not a large company by global standards.

Simply Wall St -

Do You Know About Resonance Health Limited’s (ASX:RHT) ROCE?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Understanding Return On Capital Employed (ROCE). … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Resonance Health Shareholders Have Enjoyed An Impressive 271% Share Price Gain

Resonance Health Limited (ASX:RHT) shareholders might be concerned after seeing the share price drop 10% in the last month. … One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price. … Given the importance of this milestone, it's not overly surprising that the share price has increased strongly.

Simply Wall St -

Read This Before Judging Resonance Health Limited's (ASX:RHT) ROE

To keep the lesson grounded in practicality, we'll use ROE to better understand Resonance Health Limited (ASX:RHT). … One way to conceptualize this, is that for each A$1 of shareholders' equity it has, the company made A$0.054 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Investors Should Know About Resonance Health Limited's (ASX:RHT) Financial Strength

Zero-debt allows substantial financial flexibility, especially for small-cap companies like Resonance Health Limited (ASX:RHT), as the company does not have to adhere to strict debt covenants. … However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

What Kind Of Shareholder Owns Most Resonance Health Limited (ASX:RHT) Stock?

If you want to know who really controls Resonance Health Limited (ASX:RHT), then you'll have to look at the makeup of its share registry. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Resonance Health is a smaller company with a market capitalization of AU$10m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Should You Be Concerned About Resonance Health Limited's (ASX:RHT) Investors?

In this article, I will take a quick look at Resonance Health Limited’s (ASX:RHT) recent ownership structure – an unconventional investing subject, but an important one. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

Interested In Resonance Health Limited (ASX:RHT)? Here's How It Performed Recently

This means Resonance Health has historically performed better than recently, although it seems like earnings are now heading back towards to right direction again. … ASX:RHT Income Statement Apr 11th 18 We can further analyze Resonance Health's loss by looking at what the industry has been experiencing over the past few years. … This means while Resonance Health is currently unprofitable, any near-term headwind the industry is experiencing, Resonance Health is less exposed compared to its peers.What does this mean?

Simply Wall St -

How Should You Think About Resonance Health Limited's (ASX:RHT) Risks?

If you are looking to invest in Resonance Health Limited’s (ASX:RHT), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … How RHT's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … I test RHT’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint.

Simply Wall St -

Does Resonance Health Limited (ASX:RHT) Have Enough Money Left To Grow?

See our latest analysis for Resonance Health What is cash burn? … ASX:RHT Income Statement Feb 17th 18 When will Resonance Health need to raise more cash? … This means that, if Resonance Health continues to grow its opex at this rate, given how much money it currently has in the bank, it will actually need to raise capital again in within the next 8 months!

Simply Wall St -

RHT Company Info

Description

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials, including clinical measurement, as well as project and data management services, such as reporting, administration, and support. The company serves clinicians for the diagnosis and management of human diseases; and pharmaceutical companies for their clinical trials. Resonance Health Limited has collaboration with Perth Radiological Clinic for the sharing of data and the training of neural networks to assess the viability of the development of various screening tools. The company is headquartered in Burswood, Australia.

Details
Name: Resonance Health Limited
RHT
Exchange: ASX
Founded:
A$48,299,708
402,497,568
Website: http://www.resonancehealth.com
Address: Resonance Health Limited
141 Burswood Road,
Ground Floor,
Burswood,
Western Australia, 6100,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX RHT Ordinary Shares Australian Securities Exchange AU AUD 25. Apr 1994
CHIA RHT Ordinary Shares Chi-X Australia AU AUD 25. Apr 1994
Number of employees
Current staff
Staff numbers
0
Resonance Health employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 10:31
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/02/25
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.